MedX Health Corp. Announces Approval of Debt Settlement and AGM Results
2014年6月26日 - 11:39AM
Marketwired
MedX Health Corp. Announces Approval of Debt Settlement and AGM
Results
MISSISSAUGA, ONTARIO--(Marketwired - Jun 25, 2014) - MedX Health
Corp. ("MedX" or the "Company") (TSX-VENTURE:MDX) announces that at
its Annual and Special Meeting of Shareholders held on June 24,
2014, all resolutions proposed to shareholders were duly passed,
including the approval of the issuance of 1,742,415 common shares
relating to a settlement in November, 2013 of $435,603 of debt due
to insiders of the Company. During the meeting, Gary Van Nest,
David Hennigar, Steven Guillen, Ken McKay and Robert von der Porten
were re-elected to the Board of Directors.
Following the foregoing issuance of shares in settlement of
debt, MedX will have 70,637,072 shares outstanding.
About MedX
MedX is headquartered in Mississauga, Ontario (Toronto), and is
a global leader in the design, manufacturing and distribution of
quality low level laser and light therapy technologies for use in
numerous medical settings, including rehab/chiropractic, dental,
wound care, and veterinary medicine, providing patients with drug
free and non-invasive treatment of tissue damage and pain. MedX
laser and light products are FDA approved, Health Canada cleared,
and CE Mark approved for use in North America as well as the
European Union. MedX's products include SIMSYS™ and MoleMate™,
which are approved by Health Canada, and available to Canadian
physicians and dermatologists, are FDA approved for use in the USA,
CE approved for use in Europe and the UK, and under review in
Australia, as an optical biopsy that uses patented technology
featuring a hand-held scanner device designed for clinical use that
utilizes light to view beneath suspicious moles or lesions in a
pain free, non-invasive manner, creating images in real-time for
physicians and dermatologists to evaluate all types of moles or
lesions within seconds. For more information log onto:
www.simsys-molemate.com. For a complete profile of MedX and its
products visit www.medxhealth.com.
This press release does not constitute an offer of any
securities for sale. This press release contains certain
forward-looking statements within the meaning of applicable
Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual
results to differ, including, without limitation, the company's
limited operating history and history of losses, the inability to
successfully obtain further funding, the inability to raise capital
on terms acceptable to the company, the inability to compete
effectively in the marketplace, the inability to complete the
proposed acquisition and such other risks that could cause the
actual results to differ materially from those contained in the
company's projections or forward-looking statements. All forward
looking statements in this press release are based on information
available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to
reflect events or circumstances occurring after the date of this
press release.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
MedX Health Corp.Robert von der PortenPresident and CEO905 670
4428investor@medxhealth.comwww.medxhealth.com
Medx Health (TSXV:MDX)
過去 株価チャート
から 5 2024 まで 6 2024
Medx Health (TSXV:MDX)
過去 株価チャート
から 6 2023 まで 6 2024